Verano Holdings (VRNO) Total Current Liabilities (2021 - 2026)
Verano Holdings' (VRNO) quarterly Total Current Liabilities came in at $118.9 million in Q1 2026, down 29.07% year-on-year from $167.6 million in Q1 2025, and down 15.22% on a QoQ basis from $140.3 million in Q4 2025.
Verano Holdings (VRNO) Total Current Liabilities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Total Current Liabilities data on file, last reported at $118.9 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 29.07% year-over-year to $118.9 million in Q1 2026; TTM through Mar 2026 was $118.9 million, a 29.07% decrease from a year earlier, with the FY2025 full-year figure at $140.3 million, down 30.94% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $118.9 million, down from $140.3 million in the prior quarter.
- Over the last five years, Total Current Liabilities for VRNO reached as high as $586.8 million in Q2 2022 and fell as low as $118.9 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $310.4 million across 5 years, with a median of $356.4 million in 2023.
- Across the five-year window, Total Current Liabilities advanced 23.58% in 2024 and slumped 67.06% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $386.6 million in 2022, then advanced by 6.61% to $412.2 million in 2023, then plunged by 50.72% to $203.1 million in 2024, then slumped by 30.94% to $140.3 million in 2025, then dropped by 15.22% to $118.9 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $118.9 million in Q1 2026, $140.3 million in Q4 2025, and $143.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 118.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.91 Mn |
| Dec 31, 2025 | 140.26 Mn |
| Sep 30, 2025 | 143.41 Mn |
| Jun 30, 2025 | 147.83 Mn |
| Mar 31, 2025 | 167.64 Mn |
| Dec 31, 2024 | 203.11 Mn |
| Sep 30, 2024 | 435.38 Mn |
| Jun 30, 2024 | 360.59 Mn |
| Mar 31, 2024 | 414.98 Mn |
| Dec 31, 2023 | 412.19 Mn |
| Sep 30, 2023 | 352.30 Mn |
| Jun 30, 2023 | 348.32 Mn |
| Mar 31, 2023 | 363.39 Mn |
| Dec 31, 2022 | 386.65 Mn |
| Sep 30, 2022 | 384.20 Mn |
| Jun 30, 2022 | 586.78 Mn |
| Dec 31, 2021 | 470.52 Mn |